stockrow
Friday 6 November 2026
Export BLTE’s income statement to Excel — free account
Belite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
- EPS
- −40.0%
- Free cash flow
- +64.7%
Quarter to June 2026, against a year earlier
154.46
11.27
+7.87%
Follow BLTE
Alert me
Belite Bio, Inc. Sponsored ADR (BLTE) EBITDA
Belite Bio, Inc. Sponsored ADR's EBITDA for fiscal 2025 was −$83.7M, compared with −$39.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$118.6M. Over the past ten years it has ranged from −$83.7M (fiscal 2025) to −$5.7M (fiscal 2020) — the current reading is the lowest in ten years. EBITDA has fallen for 5 consecutive fiscal years. Belite Bio, Inc. Sponsored ADR ranks 445th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$83.7M | — |
| FY2024 | −$39.5M | — |
| FY2023 | −$31.3M | — |
| FY2022 | −$12.6M | — |
| FY2021 | −$9.8M | — |
| FY2020 | −$5.7M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$34.9M | — |
| Mar 2026 | −$32.7M | — |
| Dec 2025 | −$28.0M | — |
| Sep 2025 | −$23.0M | — |
| 11 more quarters | Free account |
Against its own ten years
Low −$83.7M
High −$5.7M
Ten-year median
−$21.9M
Current reading's percentile
17
EBITDA against peers
| Company | EBITDA |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $191.8M |
| LGND Ligand Pharmaceuticals Incorporated compare | $57.3M |
| BLTE Belite Bio, Inc. Sponsored ADR | −$118.6M |
| ORKA Oruka Therapeutics, Inc. compare | −$158.0M |
| KOD Kodiak Sciences Inc. compare | −$220.8M |
| CGON CG Oncology, Inc. compare | −$250.7M |
| IMVT Immunovant, Inc. compare | −$565.6M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$579.9M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$867.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item